Backgrounds There have been conflicting reports about serum golgi protein 73 (GP73) as
one of the most promising serum markers for the diagnosis of hepatocellular carcinoma …

Conflicting results have been widely reported on the use of Golgi protein 73 (GP73) as a
serum biomarker for diagnosing hepatocellular carcinoma (HCC). This study evaluated the …

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and
the third leading cause of cancer‑related mortality worldwide. Conflicting results have been …

Background Screening of early hepatocellular carcinoma (HCC) diagnosis is the greatest
challenge for hepatologists. Alpha-fetoprotein (AFP) is the most common non-invasive …

Purpose Early detection of hepatocellular carcinoma (HCC) is essential for improved
prognosis and long-term survival. To date, screening for HCC depends on serological …

BACKGROUND Reliable biomarkers of cirrhosis, hepatocellular carcinoma (HCC), or
progression of chronic liver diseases are missing. In this context, Golgi protein-73 (GP73) …

Background Alpha-fetoprotein (AFP) has been extensively applied in clinical practice to
detect and predict postoperative outcomes of patients with hepatocellular carcinoma (HCC) …

Abstract Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of
hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the …

BACKGROUND/AIMS: Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma
(HCC). The aims of this study were to determine if GP73 is detected in the serum, and to …

Background: The up-regulation of hepatic Golgi protein 73 (GP73) is associated with the
progression of hepatocellular carcinoma (HCC). However, the exact mechanism and clinical …